While the language and descriptions were not misleading or inaccurate, the FDA raised questions regarding the proper identification required in labelling. The Company believes that the FDA inquiry will not have a material impact on its business.
At no point has the FDA raised any questions or concerns about the safety of Reed’s products, the company said. The FDA concerns relate mostly to Reed’s Natural Energy Elixir and Reed’s Nausea Relief, and do not relate to any of Reed’s or Virgil’s glass-bottled natural, carbonated soft drinks.
Reed’s is proactively and openly addressing the FDA’s labelling inquiries and has taken measures to immediately correct the FDA concerns. At this point, Reed’s is awaiting a response from the FDA on the proposed corrective measures.
Terry Foucaut, Reed’s chief operating officer, said: “The FDA seems to be increasing pressure to improve labelling and ingredient descriptions. We applaud the push toward increased disclosure. We have enthusiastically corrected these minor points in our packaging, and we look forward to closing this matter with the FDA as soon as they are able to review our responses.”
Source: Reed’s
© FoodBev Media Ltd 2024